Responses
Cervical Cancer
Immunogenicity, Reactogenicity, and Safety of Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Japanese Women: Interim Analysis of a Phase II, Double-blind, Randomized Controlled Trial at Month 7
Compose a Response to This Article
Other responses
No responses have been published for this article.